N-Acetyl-L-Leucine

Product Details

CAS No:1188-21-2

MF:C8H15NO3

Appearance:white or off-white crystalline powder

Specification:98.5%

UN number:-

Package:1/5/10/25kgs/drum

Supply Capacity:MT

Synonyms:AKOS BBS-00004735;ACETYL-DL-LEUCINE, N-;AC-LEUCINE;IFLAB-BB F0777-0821;N-ALPHA-ACETYL-L-LEUCINE;N-ALPHA-ACETYL-DL-LEUCINE;N-ACETYL LEUCINE;N-ACETYL-L-LEUCINE; N-Acetyl-L-leucine; 1188-21-2; N-Acetylleucine; L-Acetylleucine; (S)-2-Acetamido-4-methylpentanoic acid; N-acetyl-leucine; (2S)-2-acetamido-4-methylpentanoic acid; Levacetylleucine; Leucine, N-acetyl-, L-; N-ACETYL-L-(-)-LEUCINE; n-acetyl leucine; AQNEURSA; E915HL7K2O; NSC-206316; ACETYLLEUCINE, (S)-; CHEBI:17786; RefChem:927004; DTXCID00209990; 214-706-3; DTXSID40859594; acetyl-L-leucine; Ac-Leu-OH; MFCD00065131; n-acetyl-L-leucin; DTXSID6045870; L-Leucine, N-acetyl-; (2S)-2-acetamido-4-methyl-pentanoic acid; ACETYLLEUCINE, L-; KBioGR_000471; KBioSS_001793; DivK1c_001317; (2S)-2-(acetylamino)-4-methylpentanoic acid; KBio2_001793; HMS2097D14; AKOS010400978; CAS-1188-21-2; Levacetylleucine (USAN); N-Acetyl-L-leucine, ReagentPlus(R), 99%; CS-0007651; M03063; N-acetyl-Leu; AB00052251_03; LEVACETYLLEUCINE [USAN]; Leucine, N-acetyl-; DTXCID4025870; NSC 206316; UNII-E915HL7K2O; acetyl-leucine; Levacetylleucina; NCGC00094935-01; Aqneursa (TN); EINECS 214-706-3; NALL; levacetylleucine [INN]; N-acetyl-(L)-leucine; Spectrum_001313; Maybridge1_002565; Prestwick0_000896; Prestwick1_000896; Prestwick2_000896; Prestwick3_000896; Spectrum2_000475; Spectrum3_001480; Spectrum4_000036; Spectrum5_001242; Levacetylleucine [WHO-DD]; N-Acetyl-L-leucine, Vetec; BSPBio_000712; BSPBio_003039; CHEMBL56021; DivK1c_000622; SCHEMBL282372; SPECTRUM1502001; SPBio_000610; SPBio_002921; BPBio1_000784; orb1221521; orb1302557; IB1001(N-Acetyl-L-leucine); HMS501P04; HMS548M13; KBio1_000622; KBio2_004361; KBio2_006929; KBio3_002539; IB-1001(N-Acetyl-L-leucine); NINDS_000622; HMS1570D14; HMS1921B16; HMS3714D14; Pharmakon1600-01502001; AKOS BBS-00004735; Tox21_111362; CCG-40254; EBC-46236; IB1001; MSK170069; N-ACETYL-L-LEUCINE [USP-RS]; NSC758152; SBB017526; AKOS000302149; Tox21_111362_1; FA10862; FD20066; CDS1_000277; IDI1_000622; NCGC00016567-01; NCGC00016567-02; NCGC00016567-03; NCGC00016567-05; AC-22375; HY-59291; MS-20482; SY013106; SBI-0051693.P002; Argatroban Impurity 19;N-Acetyl-L-leucine; A0098; AB00513952; NS00014888; T4798; C02710; D12967; EN300-131928; N-Acetyl-L-leucine(Discontinued,SeeCPTD788393); N-Acetyl-L-leucine, Vetec(TM) reagent grade, 98%; BRD-K27406233-001-05-1; BRD-K27406233-001-07-7; Q63395724; Z756438860

Product application:N-Acetyl-L-Leucine,1188-21-2,Ac-Leu-OH,N-Acetyl-L-leucine,Levacetylleucine,N-Acetylleucine,(2S)-2-acetamido-4-methylpentanoic acid,Pharmaceutical grade N-acetyl-L-leucine,Niemann-Pick disease type C API,Cerebellar ataxia therapeutic raw material,Anti-vertigo intermediate,Vestibular neuritis API,Peptide synthesis building block,Chiral amino acid derivative,Neurodegenerative drug intermediate,Mitochondrial metabolism regulator,High purity N-Acetyl-L-Leucine 99.5%,High chiral purity 99.8% ee,CAS 1188-21-2 supplier,N-Acetyl-L-Leucine manufacturer China,Suzhou Health Chemicals chiral building blocks,N-Acetyl-L-Leucine wholesale bulk export

 

N-Acetyl-L-Leucine is widely utilized across neurodegenerative disease drug discovery, rare lysosomal storage disease therapeutics, vestibular vertigo pharmaceutical manufacturing, therapeutic peptide fragment synthesis, and cellular mitochondrial metabolism regulation sectors. In neuropharmacology and clinical rare disease therapeutics, universally designated in active enantiomeric form as Levacetylleucine, it functions as a brain-penetrant active pharmaceutical ingredient that selectively targets neuronal mitochondrial bioenergetics and lysosomal homeostasis; by normalizing disordered intracellular lipid trafficking, attenuating lysosomal storage accumulation, and stabilizing the resting membrane potentials of cerebellar Purkinje cells, it improves motor coordination, gait mechanics, and cognitive function, serving as a frontline active pharmaceutical ingredient for treating cerebellar ataxia and the progressive neurodegenerative disease Niemann-Pick type C; in otolaryngological and vestibular medicine, the molecule acts as a membrane-potential modulator for vestibular neurons, providing relief against acute vestibular neuritis, Meniere's disease, and refractory peripheral vertigo by promoting central vestibular compensation; in peptide engineering and medicinal chemistry, it operates as an enantiopure, N-terminally protected amino acid synthon for assembling therapeutic cyclic peptides, peptide-drug conjugates, and protease inhibitors without risk of racemization; furthermore, in cellular gerontology and metabolic biosciences, N-Acetyl-L-Leucine is deployed as a biochemical regulator to stimulate cellular autophagy cascades, mitigate oxidative neuroinflammation, and protect mitochondrial respiration under metabolic stress conditions.